Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
CT1812 concentrations in cerebrospinal fluid (CSF) increased in a ...
Structures of CT1812 (1), [¹⁸F]ISO-1 (2), and (3) | Download Scientific ...
Cognition Therapeutics: FDA clears IND for Oral CT1812 for geographic ...
Cognition Therapeutics Announces Positive Topline Results for CT1812 ...
CT1812 Meets Primary End Point in Phase 2 SHIMMER Study for Dementia ...
CT1812 Consistently Improves EEG Patterns in Phase 2 SEQUEL Study of ...
A Pilot Electroencephalography Study of the Effect of CT1812 Treatment ...
How CT1812 Could Enhance Synaptic Function in Alzheimer's Patients ...
Structures of UKH-1114 (1), Siramesine (2), [¹⁸F]ISO-1 (3), CT1812 (4 ...
A PILOT ELECTROENCEPHALOGRAPHY STUDY OF THE EFFECT OF CT1812 TREATMENT ...
A pilot study to evaluate the effect of CT1812 treatment on synaptic ...
CT1812 biomarker signature from a meta‐analysis of CSF proteomic ...
SHINE trial: CT1812 slows cognitive decline in Alzheimer's
CT1812 Shows Positive Results Treating Dementia With Lewy Bodies
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer ...
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer’s ...
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 ...
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In ...
The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a ...
Cognition Therapeutics publishes research on the potential of ...
GRAPHIC
Cognition Therapeutics focused on modifying degenerative disorders ...
Preclinical and clinical biomarker studies of CT1812: A novel approach ...
Cognition Therapeutics Completes Type C Meeting with FDA for ...
CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer’s ...
CTAD-2023 – Cognition Therapeutics, Inc.
Cognition Therapeutics Successfully Passes Pre-defined
Cognition Therapeutics announces dosing of first patient in MAGNIFY ...
SEQUEL (COG0202) – Cognition Therapeutics, Inc.
Cognition Therapeutics Completes End-of-Phase 2 Meeting with FDA for ...
CGTX | Cognition Therapeutics Announces Positive Topline Results for ...
Press Releases | Cognition Therapeutics, Inc. | Cognition Therapeutics ...
Cognition Therapeutics Announces Positive Results in Phase 2 Study of ...
Cognition Therapeutics' Positive Clinical Data from Zervimesine (CT1812 ...
Exploring Innovative Approaches in Alzheimer’s and Dementia Treatment
$CGTX #CT1812 Cognition Therapeutics Alzheimer's Research amyloid - YouTube
This publication offers further support of the neuroprotective ...
A Review of the Clinical Progress of CT1812, a Novel Sigma-2 Receptor ...
Cognition Therapeutics发表蛋白质组分析阐明Zervimesine在阿尔茨海默病中对神经元和突触的保护作用 - 认知障碍 ...
Chemical structure of CT1812. | Download Scientific Diagram
Cognition Therapeutics KOL Event on the Evolving Landscape in Alzheimer ...
Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on ...
Table 3 from The Allosteric Antagonist of the Sigma-2 Receptors—Elayta ...
Our approach to neurodegenerative diseases
In The News – Cognition Therapeutics, Inc.
Cognition Therapeutics (CGTX): Pipeline, Trials & Analysis | IntuitionLabs
CT-1812(CT-1812) - 药物靶点：σ2 receptor_在研适应症：路易体病，阿尔茨海默症_专利_临床_研发
Cognition Therapeutics, Inc. on LinkedIn: #ct1812 #sigma2 #aβoligomers ...
Cognition Therapeutics (CGTX): Tackling Neurodegenerative Disorders ...
A new drug has shown promise for Dementia with Lewy Bodies in the just ...
Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 ...
Cognition Therapeutics: Clinical Milestones Ignite Potential in ...
Cognition Therapeutics, Inc. on LinkedIn: Episode 5: Exploring the ...
Cognition Therapeutics announces manuscript publication on oral drug ...
Cognition Therapeutics Completes START Phase 2 Enrollment at 540 | CGTX ...
Cognition Therapeutics Announces Results of Pre-specified Analysis of ...
(PDF) Preclinical and clinical biomarker studies of CT1812: A novel ...
Identification of cerebrospinal fluid pharmacodynamic biomarkers and ...
Cognition Therapeutics Q2 2025: Breakthrough Progress in Alzheimer’s ...
#neurodegenerativediseases | Cognition Therapeutics, Inc.
2024-Keystone-iPSC-derived-neurons-as-a-model-for-S2R-function ...
CSF proteomics analysis to investigate the pharmacodynamic response of ...
Episode FIVE in this series with Cognition Therapeutics and every time ...
博腾与 Cognition Therapeutics 联合发表 OPRD 论文，彰显药物合成技术实力-最新公司动态与合作进展 | 博腾制药
Cognition Therapeutics Plans Phase 3 for Alzheimer’s Drug
#ad #alzheimersawarenessmonth #alzheimers #dementia #aging #ct1812 ...
Cognition Therapeutics, Inc. on LinkedIn: Cognition Conversations ...
Table 1 from A Pilot Electroencephalography Study of the Effect of ...
#alzheimersdisease #cognition #biotech #clinicaltrials #neuroprotective ...
速递｜穿越血脑屏障，阿尔茨海默病创新口服疗法最新临床结果发布_腾讯新闻
